DB:7AL

Stock Analysis Report

Executive Summary

Alligator Bioscience AB (publ) develops antibody-based pharmaceuticals for cancer treatment.

Rewards

Revenue is forecast to grow 75.16% per year

Risk Analysis

Has less than 1 year of cash runway

Makes less than USD$1m in revenue (SEK4M)

Currently unprofitable and not forecast to become profitable over the next 3 years

Highly volatile share price over past 3 months

+ 1 more risk


Snowflake Analysis

Excellent balance sheet with limited growth.

Share Price & News

How has Alligator Bioscience's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 7AL's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

1.5%

7AL

-1.0%

DE Biotechs

1.7%

DE Market


1 Year Return

-61.0%

7AL

6.2%

DE Biotechs

15.0%

DE Market

Return vs Industry: 7AL underperformed the German Biotechs industry which returned 6.2% over the past year.

Return vs Market: 7AL underperformed the German Market which returned 15% over the past year.


Shareholder returns

7ALIndustryMarket
7 Day1.5%-1.0%1.7%
30 Day0.7%-2.3%0.8%
90 Day-30.3%7.8%3.7%
1 Year-61.0%-61.0%6.4%6.2%18.5%15.0%
3 Year-76.0%-76.0%49.0%47.3%17.1%6.9%
5 Yearn/a12.6%10.3%24.3%7.3%

Price Volatility Vs. Market

How volatile is Alligator Bioscience's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Alligator Bioscience undervalued compared to its fair value and its price relative to the market?

2.47x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 7AL's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 7AL's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 7AL is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 7AL is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 7AL's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 7AL is good value based on its PB Ratio (2.5x) compared to the DE Biotechs industry average (3.5x).


Next Steps

Future Growth

How is Alligator Bioscience forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

9.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 7AL is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 7AL is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 7AL is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 7AL's revenue (75.2% per year) is forecast to grow faster than the German market (5% per year).

High Growth Revenue: 7AL's revenue (75.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 7AL is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Alligator Bioscience performed over the past 5 years?

-40.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 7AL is currently unprofitable.

Growing Profit Margin: 7AL is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 7AL is unprofitable, and losses have increased over the past 5 years at a rate of -40.1% per year.

Accelerating Growth: Unable to compare 7AL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 7AL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: 7AL has a negative Return on Equity (-81.28%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Alligator Bioscience's financial position?


Financial Position Analysis

Short Term Liabilities: 7AL's short term assets (SEK206.0M) exceed its short term liabilities (SEK40.9M).

Long Term Liabilities: 7AL's short term assets (SEK206.0M) exceed its long term liabilities (SEK11.7M).


Debt to Equity History and Analysis

Debt Level: 7AL is debt free.

Reducing Debt: 7AL has not had any debt for past 5 years.


Balance Sheet

Inventory Level: 7AL has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if 7AL's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 7AL has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: 7AL has less than a year of cash runway if free cash flow continues to reduce at historical rates of -41.4% each year


Next Steps

Dividend

What is Alligator Bioscience's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.3%markettop25%3.6%industryaverage1.0%forecastin3Years0%

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate 7AL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 7AL's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 7AL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 7AL's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 7AL's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.1yrs

Average management tenure


CEO

Per Norlén (49yo)

5.1yrs

Tenure

kr2,599,000

Compensation

Dr. Per Norlén has been the Chief Executive Officer at Alligator Bioscience AB (publ) since 2015 and served as its Chief Medical Officer from 2010 to January 2018 and was its Vice President of Development. ...


CEO Compensation Analysis

Compensation vs Market: Per's total compensation ($USD0.00) is below average for companies of similar size in the German market ($USD412.37K).

Compensation vs Earnings: Per's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Per Norlén
Chief Executive Officer5.1yrskr2.60m0.17% SEK100.0k
Per-Olof Schrewelius
Chief Financial Officer4.1yrsno data0.070% SEK42.4k
Malin Carlsson
Chief Operating Officer0.08yrsno datano data
Cecilia Hofvander
Director of Investor Relations & Communications0yrsno datano data
Christina Furebring
Senior Vice President of Preclinical Development19.1yrsno data0.14% SEK84.8k
Charlotte Russell
Chief Medical Officer2.1yrsno datano data

4.1yrs

Average Tenure

55yo

Average Age

Experienced Management: 7AL's management team is considered experienced (4.1 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Carl Arne Borrebäck
Non-Independent Director19.1yrskr275.00k1.68% SEK1.0m
Kenth Petersson
Independent Director19.1yrskr303.00k0.57% SEK345.9k
Peter Benson
Independent Chairman6.1yrskr500.00kno data
Kirsten Drejer
Independent Director0.8yrsno datano data
Jonas Sjögren
Independent Director5.1yrskr303.00k9% SEK5.4m
Ulrika Danielsson
Independent Director4.1yrskr392.00kno data
Anders Ekblom
Independent Director2.8yrskr295.00k0.044% SEK26.3k
Graham Dixon
Independent Director0.8yrsno datano data

4.6yrs

Average Tenure

63yo

Average Age

Experienced Board: 7AL's board of directors are considered experienced (4.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Alligator Bioscience AB (publ)'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Alligator Bioscience AB (publ)
  • Ticker: 7AL
  • Exchange: DB
  • Founded: 2001
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: kr637.500m
  • Listing Market Cap: kr60.528m
  • Shares outstanding: 71.39m
  • Website: https://www.alligatorbioscience.se

Number of Employees


Location

  • Alligator Bioscience AB (publ)
  • Medicon Village
  • Scheelevagen 2
  • Lund
  • Skåne County
  • 223 81
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ATORXOM (OMX Nordic Exchange Stockholm)YesShare CapitalSESEKNov 2016
7ALDB (Deutsche Boerse AG)YesShare CapitalDEEURNov 2016
ATORXSBATS-CHIXE (BATS 'Chi-X Europe')YesShare CapitalGBSEKNov 2016
0RK9LSE (London Stock Exchange)YesShare CapitalGBSEKNov 2016
ALLG.FOTCPK (Pink Sheets LLC)YesShare CapitalUSUSDNov 2016

Biography

Alligator Bioscience AB (publ) develops antibody-based pharmaceuticals for cancer treatment. It develops products using its technology platforms, including ALLIGATOR-GOLD, a proprietary human antibody library that contains approximately 60 billion unique antibody fragments; FIND, a molecular evolution technology for optimization of antibodies and other proteins; and bispecific fusion format for the development of novel dual-action antibodies. The company develops ADC-1013, an immunostimulatory antibody, which is in Phase I clinical trial for the treatment of metastatic cancer; and ATOR-1015, a tumor-localizing bispecific CTLA-4 and OX40 antibody, which is in Phase I clinical trial for tumor-directed treatment of metastatic cancer. Its drug candidates in preclinical development stage include ATOR-1017, an immunostimulatory antibody that binds to the costimulatory receptor 4-1BB (CD137) in tumor-specific T cells; ALG.APV-527, a bispecific 4-1BB and 5T4 antibody for the treatment of metastatic cancer; and ATOR-1144, a bispecific antibody for treating solid tumors and hematologic malignancies. The company, through its subsidiary, Atlas Therapeutics AB, also holds a stake in Biosynergy (AC101), a preclinical project. It has operations in the United States, Sweden, Asia, and internationally. The company has a partnership agreement with Aptevo Therapeutics Inc. for the co-development of ALG.APV-527; and a license agreement with Janssen Biotech, Inc. for developing ADC-1013. Alligator Bioscience AB (publ) was founded in 2001 and is headquartered in Lund, Sweden. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/16 22:48
End of Day Share Price2020/02/14 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.